Douglas Ney

Parker Institute for Cancer Immunotherapy

Also affiliated with University of Colorado Denver

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “The interim result of a phase I/II study of nivolumab with or without ipilimumab in combination with multi-fraction stereotactic radiosurgery for recurrent, high-grade, radiation-relapsed meningioma.”.

The interim result of a phase I/II study of nivolumab with or without ipilimumab in combination with multi-fraction stereotactic radiosurgery for recurrent, high-grade, radiation-relapsed meningioma.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.2068

N/A

0.373DataRank · unranked

11 citations

Feng Gao, Joshua S. Shimony, Tanner M. Johanns, Megan Mantica, Timothy R. Gershon +6 more

MEK inhibition with trametinib is a successful therapy in ganglioglioma

Clinical Case Reports and Reviews(2020)10.15761/ccrr.1000479

N/A

0DataRank · unranked

3 citations

Douglas Ney, Jean M. Mulcahy Levy, E. B. Ba

Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline

Journal of Clinical Oncology(2021)10.1200/jco.21.02036

N/A

0DataRank · unranked

191 citations

Hans Messersmith, Na Tosha Gatson, Andreas F. Hottinger, Andrew B. Lassman, Jordan Morton +14 more